In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 202 for your search:

Drug:  temozolomide
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase II/III Randomized Study of Vorinostat Versus Temozolomide Versus Bevacizumab in Combination With Local Radiotherapy Followed by Maintenance Therapy Comprising Bevacizumab and Temozolomide in Pediatric Patients With Newly Diagnosed High-Grade Glioma

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 3 to 21
Sponsor: NCI
Protocol IDs: COG-ACNS0822, ACNS0822, NCT01236560

Phase III Randomized Study of Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Patients With Recurrent Malignant Glioma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: MRC-BR12, EU-20114, ISRCTN83176944, NCT00052455

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EDOAGL-8725-001, A5921009, NCT00068952

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: C-100-21, NCT00039000

Phase III Randomized Study of Whole Brain Radiotherapy and Stereotactic Radiosurgery With Versus Without Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and Brain Metastases

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0320, NCT00096265

Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267AM2)(COMPLETED)

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P03267, NCT00091572

Radiation Therapy or Temozolomide in Treating Patients With Gliomas

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-22033-26033, 2004-002714-11, CAN-NCIC-CE5, TROG 06.01, MRC-BR13, EORTC-22033, EORTC-26033, EudraCT-2004-002714-11, CE5, NCT00182819

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A3671009, NCT00257205

Phase III Randomized Study of Adjuvant Radiation Therapy and Conventional Temozolomide Versus Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0525, EORTC-26052, EORTC-22053, NCT00304031

10.

Phase III Pilot Study of Induction Chemotherapy Followed by Consolidation Myeloablative Chemotherapy Comprising Thiotepa and Carboplatin With or Without Etoposide and Autologous Hematopoietic Stem Cell Rescue in Pediatric Patients With Previously Untreated Malignant Brain Tumors

Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 10 at diagnosis
Sponsor: Other
Protocol IDs: CHLA-HEAD-START-III, CHLA-HSIII, CHLA-2004-020, CHLA-04.020, NCT00392886, UMN-MT2004-06

11.

A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LX01-315, NCT00395070

12.

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: EMD 121974-011, EORTC 26071-22072, NCT00689221

13.

Nimotuzumab in Adults With Glioblastoma Multiforma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSAG101-BSA05, NCT00753246

14.

Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme

Phase: Phase III
Type: Health services research, Treatment
Status: Completed
Age: 60 and over
Sponsor: Other
Protocol IDs: CDR0000626713, LEONB-ET2005-006, LEONB-Nordic Glioma Adulte, INCA-RECF0031, EUDRACT-2006-003606-25, SPRI-LEONB-ET2005-006, ET2005-006, NCT00820963

15.

Phase III Randomized Study of Concurrent Chemoradiotherapy and Adjuvant Temozolomide With Versus Without Bevacizumab in Patients With Newly Diagnosed Glioblastoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0825, RTOG 0825, NCT00884741

16.

Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: IcmLCBT_301, NCT00807027

17.

A Study of Avastin (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO21990, 2008-006146-26, NCT00943826

18.

Phase I/II Study of Chemotherapy Comprising Methotrexate, Rituximab, and Temozolomide Before Radiotherapy and Temozolomide After Radiotherapy in Patients With Primary Central Nervous System Lymphoma

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0227, NCT00068250

19.

Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: ID02-126, NCT00050986

20.

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NABTT-0306 CDR0000368451, U01CA062475, ABTC-0306, NABTT-0306, NCT00085254

21.

Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 69
Sponsor: Other
Protocol IDs: EORTC-26041-22041, EORTC-26041, EORTC-22041, EUDRACT-2004-003896-35, NCT00128700

22.

Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NU 05M1, P30CA060553, NU-0310-093, SPRI-NU-05M1, NCT00301067

23.

Phase I/II Study of Motexafin Gadolinium Given Concurrently With Temozolomide and Fractionated Radiotherapy in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme or Gliosarcoma

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0513, NCT00305864

24.

Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-0428, NCT00362817

25.

Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9815, H6Q-MC-S008, NCT00402116

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map

Other Versions of this Site: Mobile | Español

Follow Us:

Twitter
YouTube
Facebook
RSS

NIH…Turning Discovery Into Health^®